Since immunohistochemical protein expression of PD-L1 is the most important predictive indicator of immunotherapy efficacy in malignant tumors clinically, we validated the relationship between LPXN and PD-L1 expression at the protein level through western blotting analysis. Here, CD274 is linked to cancer.